Keywords: Bayer, Xarelto, Visanne, VTE, Endometriosis, FDA, Europe, USA
Bayer says US filing for Xarelto delayed; Visanne cleared in Europe
Article | 7 December 2009
German drug major Bayer announced over the weekend details of data from the EINSTEIN Extension study for Xarelto (rivaroxaban), under development with US health care giant Johnson & Johnson, due to be presented at the American Society of Hematology in New Orleans conference on December 8.
There is limited new information on the EINSTEN study versus that previously seen in the abstract but there is an update on the US Food and Drug Administration regulatory status. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
